Combined targeting of BRAF and CRAF or BRAF and PI3K effector pathways is required for efficacy in NRAS mutant tumors.

Combined targeting of BRAF and CRAF or BRAF and PI3K effector pathways is required for efficacy in NRAS mutant tumors.

BACKGROUND:Oncogenic RAS is a highly validated cancer target. Attempts at targeting RAS directly have so far not succeeded in the clinic. Understanding downstream RAS-effectors that mediate oncogenesis in a RAS mutant setting will help tailor treatments that use RAS-effector inhibitors either alone...

Full description

Bibliographic Details
Main Authors: Bijay S Jaiswal, Vasantharajan Janakiraman, Noelyn M Kljavin, Jeffrey Eastham-Anderson, James E Cupp, Yuxin Liang, David P Davis, Klaus P Hoeflich, Somasekar Seshagiri
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2009-05-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC2683562?pdf=render

Internet

http://europepmc.org/articles/PMC2683562?pdf=render

Similar Items